Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
72 /100
HIGH RISK
Score updated Oct 13, 2026

CHRS — Coherus Oncology, Inc. Dilution Risk Tracker

Track CHRS dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track CHRS — Get alerts when the score changes →

As of October 13, 2026, Coherus Oncology, Inc. (CHRS) has a DilutionWatch DilutionScore of 72/100, rated HIGH dilution risk. Coherus Oncology, Inc. has a market capitalization of $159.14M, 154.50M shares outstanding, 156 institutional holders tracked. Stored dilution-related fields include ATM program capacity of $92.50M.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
62
💰 Cash Runway
65
📊 Float Risk
22
⚠️ Warrant Exposure
40
🔄 Convertible Debt
85

Dilution Forecast

⛈️
Warning
High probability of dilution event
model est. 48%
🔁 Convertible Conversion model 60%
• Major convertible overhang: 51% potential dilution
• Convertible risk score very high (85/100)
🔄 Reverse Split model est. 40%
• 50-day avg $1.71 approaching $1 threshold
• 6 months cash with weak price
💰 Capital Raise model 33%
• Under 12 months cash (6mo)
• Active ATM program with $92M remaining capacity
🔔 Track CHRS — Get forecast alerts →

Market Data

Market Cap$159.14M
Shares Outstanding154.50M
Float132.53M
Cash$105.31M
Debt$73.66M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore72/100DilutionWatch score record
Shares Outstanding154.50MVerified float table or market cache
Public Float132.53MVerified float table or market cache
Market Cap$159.14MMarket data cache
Cash Runway6.3 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM Capacity$92.50MSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 6.

Recent SEC source mix: 424B3 1, 424B5 1, 8-K 2, SC 13G 1, XBRL 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 58.0% shares (2026Q1 vs prior)
156 institutional holders · 82.94M shares
#1 BARCLAYS PLC 16.73M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 10.91M shares
#3 BlackRock, Inc. 10.37M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest23.34M
Days to Cover12.5
% of Float17.6%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2023-03-06
8-K 8K EVENT 2026-08-28
424B3 ATM 2026-08-28
SC 13G BENEFICIAL OWNERSHIP 2026-07-27
8-K 8K EVENT 2026-02-17
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual CHRS Dilution Snapshot

Coherus Oncology, Inc. (CHRS) has a DilutionScore of 72/100, rated High dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

CHRS's DilutionScore is currently 72/100 (High risk), with 4 score changes tracked over 89 days. The score improved from 71/100 (High risk).

Period Score Risk Level Duration
Oct 11 – Oct 13, 202672/100HIGH3 days
Sep 16 – Oct 10, 202671/100HIGH25 days
Aug 22 – Sep 15, 202672/100HIGH25 days
Aug 14 – Aug 21, 202664/100HIGH7 days
Jul 16 – Aug 13, 202672/100HIGH29 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

CHRS shares outstanding have increased 3.2% from 149.47M (Mar 2026) to 154.25M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 18, 2026154.25M132.53M▲ 0.38%
May 15, 2026154.25M132.02M▲ 8.56%
May 12, 2026149.89M121.61M▼ 9.00%
May 03, 2026149.89M133.64M▼ 0.34%
May 02, 2026149.89M134.09M▼ 0.45%
Apr 18, 2026149.89M134.69M▲ 0.33%
Apr 13, 2026149.89M134.25M▼ 0.28%
Mar 13, 2026149.47M134.62M▲ 0.03%
Mar 11, 2026149.47M134.58M▲ 24.01%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track CHRS Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment CHRS files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking CHRS — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for CHRS
CHRS FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.